Identification of Predictive Factors in Advanced Pancreatic Cancer Through Extracellular Vesicle Analysis

The goal of this study is to find a molecular signature that can predict response or resistance to Gemcitabine + Nab-paclitaxel therapy in pancreatic cancer (PC), to aid treatment selection for each patient. To this end, we analyzed blood-derived extracellular vesicles (EV). Overall design: EV analysis was performed on a cohort of 21 patients with PC (metastatic, locally advanced) (PCp). Samples were collected prior to first-line treatment (Gemcitabine + Nab-paclitaxel). EVs were isolated from plasma by SEC. Then we analyzed the EV RNA cargo through RNA Seq technology.

本研究旨在发掘可预测胰腺癌（PC）患者对吉西他滨联合白蛋白结合型紫杉醇治疗应答或耐药的分子特征，以辅助个体化治疗方案的选择。为此，我们针对血液来源的细胞外囊泡（extracellular vesicles, EV）展开分析。研究设计概况：本研究纳入21例胰腺癌（含转移性、局部晚期亚型）患者队列（PCp），所有受试者均在接受吉西他滨联合白蛋白结合型紫杉醇一线治疗前采集样本。我们通过尺寸排阻色谱法（SEC）从血浆中分离细胞外囊泡，随后采用RNA测序（RNA Seq）技术对囊泡内的RNA载荷进行分析。